GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ARYx Therapeutics Inc (OTCPK:ARYX) » Definitions » Asset Turnover

ARYx Therapeutics (ARYx Therapeutics) Asset Turnover : 0.00 (As of Sep. 2010)


View and export this data going back to 2007. Start your Free Trial

What is ARYx Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. ARYx Therapeutics's Revenue for the three months ended in Sep. 2010 was $0.00 Mil. ARYx Therapeutics's Total Assets for the quarter that ended in Sep. 2010 was $5.50 Mil. Therefore, ARYx Therapeutics's Asset Turnover for the quarter that ended in Sep. 2010 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. ARYx Therapeutics's annualized ROE % for the quarter that ended in Sep. 2010 was 147.15%. It is also linked to ROA % through Du Pont Formula. ARYx Therapeutics's annualized ROA % for the quarter that ended in Sep. 2010 was -183.00%.


ARYx Therapeutics Asset Turnover Historical Data

The historical data trend for ARYx Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYx Therapeutics Asset Turnover Chart

ARYx Therapeutics Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09
Asset Turnover
Get a 7-Day Free Trial - 0.11 0.07 0.33 -

ARYx Therapeutics Quarterly Data
Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ARYx Therapeutics's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, ARYx Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARYx Therapeutics's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ARYx Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where ARYx Therapeutics's Asset Turnover falls into.



ARYx Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

ARYx Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2009 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2009 )/( (Total Assets (A: Dec. 2008 )+Total Assets (A: Dec. 2009 ))/ count )
=0/( (51.148+12.406)/ 2 )
=0/31.777
=0.00

ARYx Therapeutics's Asset Turnover for the quarter that ended in Sep. 2010 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2010 )/( (Total Assets (Q: Jun. 2010 )+Total Assets (Q: Sep. 2010 ))/ count )
=0/( (5.018+5.972)/ 2 )
=0/5.495
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


ARYx Therapeutics  (OTCPK:ARYX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

ARYx Therapeutics's annulized ROE % for the quarter that ended in Sep. 2010 is

ROE %**(Q: Sep. 2010 )
=Net Income/Total Stockholders Equity
=-10.056/-6.834
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-10.056 / 0)*(0 / 5.495)*(5.495/ -6.834)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.8041
=ROA %*Equity Multiplier
=-183.00 %*-0.8041
=147.15 %

Note: The Net Income data used here is four times the quarterly (Sep. 2010) net income data. The Revenue data used here is four times the quarterly (Sep. 2010) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

ARYx Therapeutics's annulized ROA % for the quarter that ended in Sep. 2010 is

ROA %(Q: Sep. 2010 )
=Net Income/Total Assets
=-10.056/5.495
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-10.056 / 0)*(0 / 5.495)
=Net Margin %*Asset Turnover
= %*0
=-183.00 %

Note: The Net Income data used here is four times the quarterly (Sep. 2010) net income data. The Revenue data used here is four times the quarterly (Sep. 2010) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


ARYx Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of ARYx Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


ARYx Therapeutics (ARYx Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6300 Dumbarton Circle, Fremont, CA, USA, 94555
ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.
Executives
Newhall Charles W Iii 10 percent owner 1119 ST PAUL ST, BALTIMORE MD 21202
C Richard Kramlich 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Krishna Kittu Kolluri 10 percent owner
New Enterprise Associates 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea Partners 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 12 Gp, Llc 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Mark W Perry 10 percent owner
Patrick J Kerins 10 percent owner
Forest Baskett 10 percent owner
Growth Equity Opportunities Fund, Llc 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
M James Barrett 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Scott D Sandell 10 percent owner
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

ARYx Therapeutics (ARYx Therapeutics) Headlines

No Headlines